All News

For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.

Among 2000 US adults, a new survey found consumers prioritize trust and recommendations over brand loyalty in health tracking devices, prizing accuracy and reliability.

AUD affects 15 million Americans, with men nearly 2 times more vulnerable to the disease vs women. Are you tracking signs and symptoms in your patients?

Solriamfetol's significant cognitive benefits may be the result of mechanisms operating independently of its wake-promoting effects, study authors suggest.

RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.

The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.

Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.

mRNA1345 (mResvia) is now indicated for adults aged 18 to 59 years with underlying conditions including cardiovascular, respiratory, and endocrine disorders.